1357191-91-3

Upstream product

• 100-39-0 benzyl bromide 
• 1357192-01-8 1-[2-(benzyloxy)-4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl]-3-[3-(dimethylamino)prop-2-enoyl]-5-methoxypyridazin-4 (1H)-one 
• 100-63-0 phenylhydrazine 
• 1357192-00-7 3-acetyl-1-[2-(benzyloxy)-4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl]-5-methoxypyridazin-4(1H)-one 
• 1357191-99-1 1-[2-(benzyloxy)-4-(3,4-difluoro-1H-pyrrol-1-yl) phenyl]-N,5-dimethoxy-N-methyl-4-oxo-1,4-dihydropyridazine-3-carboxamide 
• 1357191-98-0 1-[2-(benzyloxy)-4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl]-5-methoxy-4-oxo-1,4-dihydropyridazine-3-carboxylic acid 
• 1357191-97-9 methyl 1-[2-(benzyloxy)-4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl]-5-methoxy-4-oxo-1,4-dihydropyridazine-3-carboxylate 
• 1357191-96-8 methyl 2-{[2-(benzyloxy)-4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl]hydrazono}-4-methoxy-3-oxobutanoate 
• 1357191-95-7 2-(benzyloxy)-4-(3,4-difluoro-1H-pyrrol-1-yl)aniline 
• 1357191-94-6 1-[3-(benzyloxy)-4-nitrophenyl]-3,4-difluoro-1H-pyrrole 
• 1357191-93-5 5-(3,4-difluoro-1H-pyrrol-1-yl)-2-nitrophenol 
• 1357191-92-4 1-(3-tert-butoxy-4-nitrophenyl)-3,4-difluoro-1H-pyrrole 
• 1187386-34-0 4-bromo-2-(tert-butoxy)-1-nitrobenzene 
• 321-23-3 4-bromo-2-fluoronitrobenzene 

Downstream Products

• 1357192-02-9 1-[4-(3,4-difluoro-1H-pyrrol-1-yl)-2-hydroxyphenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one 
• 1357192-03-0 1-[4-(3,4-difluoro-1H-pyrrol-1-yl)-2-methoxyphenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one 
• 1357192-04-1 1-[2-(difluoromethoxy)-4-(3,4-difluoro-1H-pyrrol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one 
• 1357192-05-2 1-[4-(3,4-difluoro-1H-pyrrol-1-yl)-2-(2,2,2-trifluoroethoxy)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one 

Relevant academic research and scientific papers

RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS

The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of PDE10A in mammals. The compound of the present invention is represented by the formula (I): wherein each symbols are as defined in the specification.

HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.